1. Home
  2. OCGN vs ALT Comparison

OCGN vs ALT Comparison

Compare OCGN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • ALT
  • Stock Information
  • Founded
  • OCGN 2013
  • ALT 1997
  • Country
  • OCGN United States
  • ALT United States
  • Employees
  • OCGN N/A
  • ALT N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • OCGN Health Care
  • ALT Health Care
  • Exchange
  • OCGN Nasdaq
  • ALT Nasdaq
  • Market Cap
  • OCGN 321.7M
  • ALT 327.4M
  • IPO Year
  • OCGN N/A
  • ALT N/A
  • Fundamental
  • Price
  • OCGN $1.39
  • ALT $3.84
  • Analyst Decision
  • OCGN Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • OCGN 3
  • ALT 6
  • Target Price
  • OCGN $6.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • OCGN 2.6M
  • ALT 2.3M
  • Earning Date
  • OCGN 11-07-2025
  • ALT 11-11-2025
  • Dividend Yield
  • OCGN N/A
  • ALT N/A
  • EPS Growth
  • OCGN N/A
  • ALT N/A
  • EPS
  • OCGN N/A
  • ALT N/A
  • Revenue
  • OCGN $4,754,000.00
  • ALT $20,000.00
  • Revenue This Year
  • OCGN N/A
  • ALT N/A
  • Revenue Next Year
  • OCGN N/A
  • ALT $761,880.20
  • P/E Ratio
  • OCGN N/A
  • ALT N/A
  • Revenue Growth
  • OCGN N/A
  • ALT N/A
  • 52 Week Low
  • OCGN $0.52
  • ALT $2.90
  • 52 Week High
  • OCGN $1.33
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 83.73
  • ALT 54.41
  • Support Level
  • OCGN $1.00
  • ALT $3.56
  • Resistance Level
  • OCGN $1.25
  • ALT $3.72
  • Average True Range (ATR)
  • OCGN 0.06
  • ALT 0.18
  • MACD
  • OCGN 0.04
  • ALT 0.03
  • Stochastic Oscillator
  • OCGN 92.69
  • ALT 45.80

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: